Effectiveness of ranitidine bismuth citrate and proton pump inhibitor based triple therapies of Helicobacter pylori in Turkey

Figures & data

Table 1. Characteristics of the patients and eradication rates in the six groups

Characteristics	RBC-AC	OAC	LAC	RAC	PAC	EsAC
Number of patients (ITT)	66	66	66	66	66	66
Reason for drop out
Side effects	1	1	2	1	0	1
Poor compliance	1	1	1	0	1	1
Lost to follow-up	1	0	2	1	1	1
Number of patients (PP)	63	64	61	64	64	63
Age (mean±SD)	36.2±10.4	39.6±12.6	38.9±11.6	35.3±7.7	37.6±10.2	36.4±8.4
Male/female	37/26	35/29	35/26	37/27	33/31	37/26
Smoker number (%)	26 (41.3%)	26 (40.6%)	23 (37.7%)	24 (37.5%)	25 (39.1%)	23 (36.5%)
Aspirin user number (%)	8 (12.7%)	9 (14.1%)	7 (11.5%)	10 (15.6%)	10 (15.6%)	9 (14.3%)
NSAID user (%)	10 (15.9%)	15 (23.4%)	12 (19.7%)	14 (21.9%)	12 (18.8%)	12 (19.1%)
Peptic ulcer number (%)	14 (22.2%)	14 (21.9%)	16 (26.2%)	16 (25%)	17 (26.6%)	16 (25.4%)
Eradication number (%) Intention to treat Per protocol	54/66 (81.8%)* 54/63 (85.7%)*	42/66 (63.6%) 42/64 (65.6%)	44/66 (66.7%) 44/61 (72.1%)	54/66 (81.8%)* 54/64 (84.4%)*	40/66 (60.6%) 40/64 (62.5%)	38/65 (57.6%) 38/63 (60.3%)

*p<0.05 according to other groups.

Abbreviations: RBC: ranitidine bismuth citrate, A: amoxicillin, C: clarithromycin, O: omeprazole, L: lansoprazole, R: rabeprazole, P: pantoprazole, Es: esomeprazole, NSAID: non-steroid anti-inflammatory drugs.

Table 2. Eradication rates in different subgroups

Characteristic	Group	Total number	Eradicated number (%)
Completion of study	All patients Completed study	396 379	272 (68.7%) 272 (71.8%)
Gender	Male Female	214 165	147 (68.7%) 125 (75.8%)
Smoking	Yes No	147 232	103 (70.1%) 169 (72.8%)
Aspirin use	Yes No	53 326	40 (75.5%) 232 (71%)
NSAID use	Yes No	75 304	50 (73.3%) 217 (71.4%)
Peptic ulcer H. pylori gastritis	— —	94 285	68 (72.3%) 204 (71.6%)

Note: Statistically significant difference was not present between the groups.